{
  "slug": "fresenius-kabi",
  "name": "Fresenius Kabi",
  "description": "TYENNE (tocilizumab-aazg) is an FDA-approved biosimilar to Actemra® (tocilizumab) for the treatment of various inflammatory and autoimmune conditions, including moderately to severely active rheumatoid arthritis, giant cell arteritis, polyarticular and systemic juvenile idiopathic arthritis, CAR T cell-induced severe or life-threatening cytokine release syndrome, and hospitalized adult patients with COVID-19. It offers three administration options, including a pre-filled autoinjector pen.",
  "url": "https://optimly.ai/brand/fresenius-kabi",
  "websiteUrl": "https://biosimilars.fresenius-kabi.com/",
  "logoUrl": "https://logo.clearbit.com/biosimilars.fresenius-kabi.com",
  "baiScore": 43.3,
  "bai_tier_status": "active",
  "bai_score_status": "active",
  "archetype": null,
  "archetype_status": "active",
  "category": "Prescription Pharmaceutical Medicines",
  "categorySlug": null,
  "keyFacts": [],
  "aiReadiness": [],
  "competitors": [],
  "competitorsProse": null,
  "inboundCompetitors": [],
  "aiAlternatives": [],
  "parentBrand": null,
  "subBrands": [],
  "updatedAt": "2026-08-17T22:08:05.800Z",
  "verifiedVitals": {
    "website": "https://biosimilars.fresenius-kabi.com",
    "category": "Biopharmaceutical",
    "what_it_does": "TYENNE® (tocilizumab-aazg) is an FDA-approved biosimilar indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA), giant cell arteritis (GCA), active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older, active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older, chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older, and coronavirus disease 2019 (COVID-19) in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).",
    "primary_audience": "Adult and pediatric patients (2 years of age and older) with specific medical conditions, their caregivers, and healthcare professionals.",
    "core_product": "TYENNE® (tocilizumab-aazg)",
    "pricing_model": {
      "kind": "custom",
      "detail": "Pricing involves established Q-codes and payer coverage, requiring contact with an Account Manager or Field Reimbursement Manager for details."
    },
    "parent_ownership": "Fresenius Kabi",
    "named_competitors": [
      "Actemra® (tocilizumab)"
    ]
  },
  "intentTags": null,
  "businessProfileClaims": [],
  "timestamp": 1788317774911
}